Vaxcyte's VAX-31 vaccine meets all phase 3 trial endpoints

October 5, 2026 6:00 AM

Vaxcyte, Inc. (Nasdaq: PCVX) announced positive topline results from OPUS-1, a pivotal adult Phase 3 trial evaluating VAX-31, its 31-valent ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found